Literature DB >> 1849973

Establishment of latency in vitro by the herpes simplex virus type 1 mutant in1814.

R A Harris1, C M Preston.   

Abstract

The herpes simplex virus type 1 (HSV-1) mutant in1814 possesses an insertion mutation that abolishes trans-activation of immediate early (IE) transcription by the virion protein Vmw65. Interactions between in1814 and the host cell were examined by use of an in vitro latency system which relies on infection of human foetal lung (HFL) cells at 42 degrees C to prevent lytic growth of virus. Mutant in1814 was retained in HFL cells after infection at low m.o.i. and incubation at 42 degrees C, and was reactivated by superinfection of monolayers with viruses that express the HSV-1 IE protein Vmw110. Moreover, latency was established by in1814 in an analogous manner at 37 degrees C. The low cytotoxicity of in1814 enabled an investigation of latency after infection at high m.o.i. (five particles per cell) to be undertaken. At 42 degrees C, or at 37 degrees C in the presence of an inhibitor of DNA synthesis, in1814 DNA was maintained at low abundance (one to eight copies per infected cell) in a non-linear configuration. The absence of trans-activation by Vmw65 therefore predisposes HSV to latency, as opposed to lytic growth, in HFL cells, resulting in the retention of the genome in a form resembling that found in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849973     DOI: 10.1099/0022-1317-72-4-907

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  34 in total

1.  Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0.

Authors:  K L Mossman; J R Smiley
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  VP16 serine 375 is a critical determinant of herpes simplex virus exit from latency in vivo.

Authors:  Nancy M Sawtell; Steven J Triezenberg; Richard L Thompson
Journal:  J Neurovirol       Date:  2011-12-06       Impact factor: 2.643

3.  Characterization of a potent refractory state and persistence of herpes simplex virus 1 in cell culture.

Authors:  Cristina Barreca; Peter O'Hare
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis.

Authors:  C M Preston; M J Nicholl
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Herpes simplex virus VP16, but not ICP0, is required to reduce histone occupancy and enhance histone acetylation on viral genomes in U2OS osteosarcoma cells.

Authors:  Meaghan H Hancock; Anna R Cliffe; David M Knipe; James R Smiley
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

6.  Abortive herpes simplex virus infection of nonneuronal cells results in quiescent viral genomes that can reactivate.

Authors:  Efrat M Cohen; Nir Avital; Meir Shamay; Oren Kobiler
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-23       Impact factor: 11.205

Review 7.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

8.  Human cytomegalovirus tegument protein pp71 directs long-term gene expression from quiescent herpes simplex virus genomes.

Authors:  Chris M Preston; Mary Jane Nicholl
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells.

Authors:  Craig S Miller; Robert J Danaher; Robert J Jacob
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Histone modifications associated with herpes simplex virus type 1 genomes during quiescence and following ICP0-mediated de-repression.

Authors:  Heather M Coleman; Viv Connor; Zara S C Cheng; Finn Grey; Chris M Preston; Stacey Efstathiou
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.